;PMID: 2283667
;source_file_1931.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..211] = [t:47..211]
;2)section:[e:215..269] = [t:215..269]
;3)section:[e:273..315] = [t:273..315]
;4)sentence:[e:319..585] = [t:319..585]
;5)sentence:[e:586..742] = [t:586..742]
;6)sentence:[e:743..972] = [t:743..972]
;7)sentence:[e:973..1054] = [t:973..1054]
;8)sentence:[e:1055..1165] = [t:1055..1165]
;9)sentence:[e:1166..1330] = [t:1166..1330]
;10)sentence:[e:1331..1447] = [t:1331..1447]
;11)sentence:[e:1448..1543] = [t:1448..1543]
;12)sentence:[e:1544..1668] = [t:1544..1668]
;13)sentence:[e:1669..1848] = [t:1669..1848]
;14)section:[e:1852..1896] = [t:1852..1896]

;section 0 Span:0..41
;J Biochem Toxicol. 1990 Fall;5(3):167-74.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Biochem) (NNP:[10..17] Toxicol)
        (.:[17..18] .) (CD:[19..23] 1990) (NN:[24..30] Fall;5)
        (-LRB-:[30..31] -LRB-) (CD:[31..32] 3) (-RRB-:[32..33] -RRB-)
        (CD:[33..37] :167) (::[37..38] -) (CD:[38..40] 74) (.:[40..41] .)))

;sentence 1 Span:47..211
;Inhibition of carbon tetrachloride-induced lipid peroxidation by novel 
;antioxidants in rat hepatic microsomes: dissociation from hepatoprotective 
;effects in vivo.
;[61..81]:substance:"carbon tetrachloride"
;[90..95]:substance:"lipid"
;[119..131]:substance:"antioxidants"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[47..57] Inhibition))
      (PP (IN:[58..60] of)
        (NP
          (ADJP
            (NML (NN:[61..67] carbon) (NN:[68..81] tetrachloride))
            (HYPH:[81..82] -) (VBN:[82..89] induced))
          (NN:[90..95] lipid) (NN:[96..108] peroxidation)))
      (PP (IN:[109..111] by)
        (NP (JJ:[112..117] novel) (NNS:[119..131] antioxidants)))
      (PP-LOC (IN:[132..134] in)
        (NP (NN:[135..138] rat) (JJ:[139..146] hepatic)
            (NNS:[147..157] microsomes))))
    (::[157..158] :)
    (NP
      (NP (NN:[159..171] dissociation))
      (PP (IN:[172..176] from)
        (NP (JJ:[177..193] hepatoprotective) (NNS:[195..202] effects)))
      (ADJP (FW:[203..205] in) (FW:[206..210] vivo)))
    (.:[210..211] .)))

;section 2 Span:215..269
;Wolfgang GH, Jolly RA, Donarski WJ, Ochoa R, Petry TW.
(SEC
  (FRAG (NNP:[215..223] Wolfgang) (NNP:[224..226] GH) (,:[226..227] ,)
        (NNP:[228..233] Jolly) (NNP:[234..236] RA) (,:[236..237] ,)
        (NNP:[238..246] Donarski) (NNP:[247..249] WJ) (,:[249..250] ,)
        (NNP:[251..256] Ochoa) (NNP:[257..258] R) (,:[258..259] ,)
        (NNP:[260..265] Petry) (NNP:[266..268] TW) (.:[268..269] .)))

;section 3 Span:273..315
;Upjohn Company, Kalamazoo, Michigan 49001.
(SEC
  (FRAG (NNP:[273..279] Upjohn) (NNP:[280..287] Company) (,:[287..288] ,)
        (NNP:[289..298] Kalamazoo) (,:[298..299] ,) (NNP:[300..308] Michigan)
        (CD:[309..314] 49001) (.:[314..315] .)))

;sentence 4 Span:319..585
;The ability of two novel antioxidants, U-74,006F and U-78,517G, as well as
;the  known antioxidant N,N'-diphenyl-p-phenylenediamine to inhibit lipid
;peroxidation  induced by carbon tetrachloride (CCl4) was investigated in
;Aroclor 1254-induced  rat hepatic microsomes.
;[344..356]:substance:"antioxidants"
;[358..367]:substance:"U-74,006F"
;[372..381]:substance:"U-78,517G"
;[405..416]:substance:"antioxidant"
;[417..449]:substance:"N,N'-diphenyl-p-phenylenediamine"
;[461..466]:substance:"lipid"
;[492..512]:substance:"carbon tetrachloride"
;[514..518]:substance:"CCl4"
;[540..552]:substance:"Aroclor 1254"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[319..322] The) (NN:[323..330] ability)
        (S-2 (-NONE-:[330..330] *ICH*)))
      (PP (IN:[331..333] of)
        (NP
          (NP
            (NP (CD:[334..337] two) (JJ:[338..343] novel)
                (NNS:[344..356] antioxidants))
            (,:[356..357] ,)
            (NP (NN:[358..367] U-74,006F) (CC:[368..371] and)
                (NN:[372..381] U-78,517G)))
          (,:[381..382] ,)
          (CONJP (RB:[383..385] as) (RB:[386..390] well) (IN:[391..393] as))
          (NP
            (NP (DT:[394..397] the) (VBN:[399..404] known)
                (NN:[405..416] antioxidant))
            (NP (NN:[417..449] N,N'-diphenyl-p-phenylenediamine)))))
      (S-2
        (NP-SBJ (-NONE-:[449..449] *))
        (VP (TO:[450..452] to)
          (VP (VB:[453..460] inhibit)
            (NP
              (NP (NN:[461..466] lipid) (NN:[467..479] peroxidation))
              (VP (VBN:[481..488] induced)
                (NP (-NONE-:[488..488] *))
                (PP (IN:[489..491] by)
                  (NP-LGS
                    (NP (NN:[492..498] carbon) (NN:[499..512] tetrachloride))
                    (NP (-LRB-:[513..514] -LRB-) (NN:[514..518] CCl4)
                        (-RRB-:[518..519] -RRB-))))))))))
    (VP (VBD:[520..523] was)
      (VP (VBN:[524..536] investigated)
        (NP-1 (-NONE-:[536..536] *))
        (PP-LOC (IN:[537..539] in)
          (NP
            (ADJP
              (NML (NNP:[540..547] Aroclor) (CD:[548..552] 1254))
              (HYPH:[552..553] -) (VBN:[553..560] induced))
            (NN:[562..565] rat) (JJ:[566..573] hepatic)
             (NNS:[574..584] microsomes)))))
    (.:[584..585] .)))

;sentence 5 Span:586..742
;All three compounds completely inhibited lipid  peroxidation in microsomes as
;measured by the formation of thiobarbituric acid  reactive substances
;(TBARS).
;[596..605]:substance:"compounds"
;[627..632]:substance:"lipid"
;[693..733]:substance:"thiobarbituric acid  reactive substances"
;[735..740]:substance:"TBARS"
(SENT
  (S
    (NP-SBJ (DT:[586..589] All) (CD:[590..595] three) (NNS:[596..605] compounds))
    (ADVP (RB:[606..616] completely))
    (VP (VBD:[617..626] inhibited)
      (NP (NN:[627..632] lipid) (NN:[634..646] peroxidation))
      (PP-LOC (IN:[647..649] in)
        (NP (NNS:[650..660] microsomes)))
      (SBAR-ADV (IN:[661..663] as)
        (S
          (NP-SBJ-1 (-NONE-:[663..663] *))
          (VP (VBN:[664..672] measured)
            (NP-1 (-NONE-:[672..672] *))
            (PP-MNR (IN:[673..675] by)
              (NP
                (NP (DT:[676..679] the) (NN:[680..689] formation))
                (PP (IN:[690..692] of)
                  (NP
                    (NP
                      (ADJP
                        (NML (JJ:[693..707] thiobarbituric) (NN:[708..712] acid))
                        (JJ:[714..722] reactive))
                      (NNS:[723..733] substances))
                    (NP (-LRB-:[734..735] -LRB-) (NN:[735..740] TBARS)
                        (-RRB-:[740..741] -RRB-))))))))))
    (.:[741..742] .)))

;sentence 6 Span:743..972
;Inhibition of lipid peroxidation was not a function  of decreased
;bioactivation of CCl4, as the compounds did not substantially  inhibit
;benzphetamine N-demethylase activity or covalent binding of [14-C]CCl4  to
;lipid or protein.
;[757..762]:substance:"lipid"
;[826..830]:substance:"CCl4"
;[839..848]:substance:"compounds"
;[880..907]:cyp450:"benzphetamine N-demethylase"
;[940..950]:substance:"[14-C]CCl4"
;[955..960]:substance:"lipid"
;[964..971]:substance:"protein"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[743..753] Inhibition))
      (PP (IN:[754..756] of)
        (NP (NN:[757..762] lipid) (NN:[763..775] peroxidation))))
    (VP (VBD:[776..779] was) (RB:[780..783] not)
      (NP-PRD
        (NP (DT:[784..785] a) (NN:[786..794] function))
        (PP (IN:[796..798] of)
          (NP
            (NP (VBN:[799..808] decreased) (NN:[809..822] bioactivation))
            (PP (IN:[823..825] of)
              (NP (NN:[826..830] CCl4))))))
      (,:[830..831] ,)
      (SBAR-ADV (IN:[832..834] as)
        (S
          (NP-SBJ (DT:[835..838] the) (NNS:[839..848] compounds))
          (VP (VBD:[849..852] did) (RB:[853..856] not)
            (ADVP (RB:[857..870] substantially))
            (VP (VB:[872..879] inhibit)
              (NP
                (NP
                   (NN:[880..893] benzphetamine) (NN:[894..907] N-demethylase)
                  (NN:[908..916] activity))
                (CC:[917..919] or)
                (NP
                  (NP (JJ:[920..928] covalent) (NN:[929..936] binding))
                  (PP (IN:[937..939] of)
                    (NP (NN:[940..950] -LSB-14-C-RSB-CCl4)))
                  (PP (TO:[952..954] to)
                    (NP (NN:[955..960] lipid) (CC:[961..963] or)
                        (NN:[964..971] protein))))))))))
    (.:[971..972] .)))

;sentence 7 Span:973..1054
;Parallel studies examined the hepatoprotective effects of  the compounds in
;vivo.
;[1036..1045]:substance:"compounds"
(SENT
  (S
    (NP-SBJ (JJ:[973..981] Parallel) (NNS:[982..989] studies))
    (VP (VBD:[990..998] examined)
      (NP
        (NP (DT:[999..1002] the) (JJ:[1003..1019] hepatoprotective)
            (NNS:[1020..1027] effects))
        (PP (IN:[1028..1030] of)
          (NP (DT:[1032..1035] the) (NNS:[1036..1045] compounds))))
      (ADVP (FW:[1046..1048] in) (FW:[1049..1053] vivo)))
    (.:[1053..1054] .)))

;sentence 8 Span:1055..1165
;Rats were pretreated with antioxidant or vehicle prior to  administration of
;CCl4 (300 or 600 microL/kg i.p.).
;[1081..1092]:substance:"antioxidant"
;[1132..1136]:substance:"CCl4"
;[1138..1141]:quantitative-value:"300"
;[1145..1148]:quantitative-value:"600"
;[1149..1158]:quantitative-units:"microL/kg"
(SENT
  (S
    (NP-SBJ-2 (NNS:[1055..1059] Rats))
    (VP (VBD:[1060..1064] were)
      (VP (VBN:[1065..1075] pretreated)
        (NP-2 (-NONE-:[1075..1075] *))
        (PP (IN:[1076..1080] with)
          (NP (NN:[1081..1092] antioxidant) (CC:[1093..1095] or)
              (NN:[1096..1103] vehicle)))
        (PP-TMP (JJ:[1104..1109] prior)
          (PP (TO:[1110..1112] to)
            (NP
              (NP
                (NP (NN:[1114..1128] administration))
                (PP (IN:[1129..1131] of)
                  (NP (NN:[1132..1136] CCl4))))
              (PRN (-LRB-:[1137..1138] -LRB-)
                (FRAG
                  (NP
                    (NP
                      (NP (CD:[1138..1141] 300)
                        (NML-1 (-NONE-:[1141..1141] *P*)))
                      (CC:[1142..1144] or)
                      (NP (CD:[1145..1148] 600)
                        (NML-1 (NN:[1149..1155] microL))))
                    (PP (SYM:[1155..1156] /)
                      (NP (NN:[1156..1158] kg))))
                  (ADVP (RB:[1159..1163] i.p.)))
                (-RRB-:[1163..1164] -RRB-)))))))
    (.:[1164..1165] .)))

;sentence 9 Span:1166..1330
;Sera were collected 24 h  postadministration of CCl4 and analyzed for alanine
;aminotransferase (ALT) and  alkaline phosphatase (ALP) activities and total
;bilirubin.
;[1186..1188]:quantitative-value:"24"
;[1189..1190]:quantitative-units:"h"
;[1214..1218]:substance:"CCl4"
;[1236..1260]:substance:"alanine aminotransferase"
;[1262..1265]:substance:"ALT"
;[1272..1292]:substance:"alkaline phosphatase"
;[1294..1297]:substance:"ALP"
;[1320..1329]:substance:"bilirubin"
(SENT
  (S
    (NP-SBJ-2 (NNS:[1166..1170] Sera))
    (VP (VBD:[1171..1175] were)
      (VP
        (VP (VBN:[1176..1185] collected)
          (NP-2 (-NONE-:[1185..1185] *))
          (ADVP-TMP
            (NP-ADV (CD:[1186..1188] 24) (NN:[1189..1190] h))
            (RB:[1192..1210] postadministration)
            (PP (IN:[1211..1213] of)
              (NP (NN:[1214..1218] CCl4)))))
        (CC:[1219..1222] and)
        (VP (VBN:[1223..1231] analyzed)
          (NP-2 (-NONE-:[1231..1231] *))
          (PP (IN:[1232..1235] for)
            (NP
              (NP
                (NP
                  (NML
                    (NML (NN:[1236..1243] alanine)
                         (NN:[1244..1260] aminotransferase))
                    (NML (-LRB-:[1261..1262] -LRB-) (NN:[1262..1265] ALT)
                         (-RRB-:[1265..1266] -RRB-)))
                  (NML-1 (-NONE-:[1266..1266] *P*)))
                (CC:[1267..1270] and)
                (NP
                  (NML
                    (NML (NN:[1272..1280] alkaline)
                         (NN:[1281..1292] phosphatase))
                    (NML (-LRB-:[1293..1294] -LRB-) (NN:[1294..1297] ALP)
                         (-RRB-:[1297..1298] -RRB-)))
                  (NML-1 (NNS:[1299..1309] activities))))
              (CC:[1310..1313] and)
              (NP (JJ:[1314..1319] total) (NN:[1320..1329] bilirubin)))))))
    (.:[1329..1330] .)))

;sentence 10 Span:1331..1447
;Administration of  CCl4 produced elevations in ALT, moderate changes in
;bilirubin, and no change in  ALP activities.
;[1350..1354]:substance:"CCl4"
;[1378..1381]:substance:"ALT"
;[1403..1412]:substance:"bilirubin"
;[1432..1435]:substance:"ALP"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1331..1345] Administration))
      (PP (IN:[1346..1348] of)
        (NP (NN:[1350..1354] CCl4))))
    (VP (VBD:[1355..1363] produced)
      (NP
        (NP
          (NP (NNS:[1364..1374] elevations))
          (PP (IN:[1375..1377] in)
            (NP (NN:[1378..1381] ALT))))
        (,:[1381..1382] ,)
        (NP
          (NP (JJ:[1383..1391] moderate) (NNS:[1392..1399] changes))
          (PP (IN:[1400..1402] in)
            (NP (NN:[1403..1412] bilirubin))))
        (,:[1412..1413] ,) (CC:[1414..1417] and)
        (NP
          (NP (DT:[1418..1420] no) (NN:[1421..1427] change))
          (PP (IN:[1428..1430] in)
            (NP (NN:[1432..1435] ALP) (NNS:[1436..1446] activities))))))
    (.:[1446..1447] .)))

;sentence 11 Span:1448..1543
;Histological examination of CCl4-treated livers revealed  lipidosis and
;centrilobular necrosis.
;[1476..1480]:substance:"CCl4"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1448..1460] Histological) (NN:[1461..1472] examination))
      (PP (IN:[1473..1475] of)
        (NP
          (ADJP (NN:[1476..1480] CCl4) (HYPH:[1480..1481] -)
                (VBN:[1481..1488] treated))
          (NNS:[1489..1495] livers))))
    (VP (VBD:[1496..1504] revealed)
      (NP
        (NP (NN:[1506..1515] lipidosis))
        (CC:[1516..1519] and)
        (NP (JJ:[1520..1533] centrilobular) (NN:[1534..1542] necrosis))))
    (.:[1542..1543] .)))

;sentence 12 Span:1544..1668
;The antioxidants partially improved the  clinical chemistry parameters, but
;had minimal effects on the histological  lesion.
;[1548..1560]:substance:"antioxidants"
(SENT
  (S
    (NP-SBJ (DT:[1544..1547] The) (NNS:[1548..1560] antioxidants))
    (VP
      (VP
        (ADVP (RB:[1561..1570] partially))
        (VBD:[1571..1579] improved)
        (NP (DT:[1580..1583] the) (JJ:[1585..1593] clinical)
            (NN:[1594..1603] chemistry) (NNS:[1604..1614] parameters)))
      (,:[1614..1615] ,) (CC:[1616..1619] but)
      (VP (VBD:[1620..1623] had)
        (NP (JJ:[1624..1631] minimal) (NNS:[1632..1639] effects))
        (PP (IN:[1640..1642] on)
          (NP (DT:[1643..1646] the) (JJ:[1647..1659] histological)
              (NN:[1661..1667] lesion)))))
    (.:[1667..1668] .)))

;sentence 13 Span:1669..1848
;In contrast to the complete inhibition of lipid peroxidation observed in  the
;in vitro studies, none of the antioxidants markedly protected against 
;CCl4-induced toxicity in vivo.
;[1711..1716]:substance:"lipid"
;[1777..1789]:substance:"antioxidants"
;[1818..1822]:substance:"CCl4"
(SENT
  (S
    (PP (IN:[1669..1671] In)
      (NP
        (NP (NN:[1672..1680] contrast))
        (PP (TO:[1681..1683] to)
          (NP
            (NP
              (NP (DT:[1684..1687] the) (JJ:[1688..1696] complete)
                  (NN:[1697..1707] inhibition))
              (PP (IN:[1708..1710] of)
                (NP (NN:[1711..1716] lipid) (NN:[1717..1729] peroxidation))))
            (VP (VBN:[1730..1738] observed)
              (NP (-NONE-:[1738..1738] *))
              (PP-LOC (IN:[1739..1741] in)
                (NP (DT:[1743..1746] the)
                  (ADJP (FW:[1747..1749] in) (FW:[1750..1755] vitro))
                  (NNS:[1756..1763] studies))))))))
    (,:[1763..1764] ,)
    (NP-SBJ
      (NP (NN:[1765..1769] none))
      (PP (IN:[1770..1772] of)
        (NP (DT:[1773..1776] the) (NNS:[1777..1789] antioxidants))))
    (ADVP (RB:[1790..1798] markedly))
    (VP (VBD:[1799..1808] protected)
      (PP (IN:[1809..1816] against)
        (NP
          (ADJP (NN:[1818..1822] CCl4) (HYPH:[1822..1823] -)
                (VBN:[1823..1830] induced))
          (NN:[1831..1839] toxicity)))
      (ADVP (FW:[1840..1842] in) (FW:[1843..1847] vivo)))
    (.:[1847..1848] .)))

;section 14 Span:1852..1896
;PMID: 2283667 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1852..1856] PMID) (::[1856..1857] :) (CD:[1858..1865] 2283667)
        (NN:[1866..1867] -LSB-) (NNP:[1867..1873] PubMed) (::[1874..1875] -)
        (NN:[1876..1883] indexed) (IN:[1884..1887] for)
        (NNP:[1888..1896] MEDLINE-RSB-)))
